Perhaps unsurprisingly, it appears to be true that “AR gain” (see below) does indeed lower overall survival (OS) and progression-free survival (PFS) rates among men with castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, AR, ARSI, castration-resistant, CRPC, gain, inhibitor, receptor, signaling | 3 Comments »
Back in December 2017, Pfizer started a trial to explore whether the PARP inhibitor talazoparib (Talzenna) could be used in combination with enzalutamide (Xtandi) to effectively treat men with what are known as MSI-H or dMMR subtypes of metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: inhibitor, mCRPC, niraparib, olaparib, PARP, Phase III, rucaparib, talazoparib | 5 Comments »
A paper in the journal Oncotarget has suggested that patients who have progressed on treatment with enzalutamide (Xtandi) may be good candidates for treatment with one of the checkpoint inhibitors like pembrolizumab (Keytruda), nivolumab (Opdivo), or even ipilimumab (Yervoy). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, checkpoiny, CRPC, enzalutamide, inhibitor, resistant | Leave a comment »
A poster presented at the ESMO meeting in Munich has just reported data from an unplanned, preliminary analysis of data from the first 85 patients (out of a scheduled total of 150 patients) enrolled in the TRITON 2 trial of the PARP inhibitor rucaparib (Rubraca) … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: inhibitor, PARP, Rubraca, rucaparib, trial, TRITON 2 | 2 Comments »
Immune checkpoint inhibitors include drugs like ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), and others that can have dramatic effects on the survival of some groups of patients with advanced forms of some cancers. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antibody, checkpoint, immune, inhibitor, outcome, test, trial | 4 Comments »
There are now two, ongoing, Phase III trials of PARP inhibitors in the treatment of eligible patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: inhibitor, mCRPC, PARP, Phase III, trial | Leave a comment »
A second PARP inhibitor has recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with BRCA1/2 mutations and advanced ovarian cancer who have already received two types of chemotherapy. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: advanced, BRCA1/2, inhibitor, PARP | 3 Comments »
New immunotherapeutic drugs known as PD-1 inhibitors (drugs like nivolumab/Optivo and pembrolizumab/Keytruda) have shown some remarkable effects in the treatment of advanced forms of cancer like melanoma and some forms of lung cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, efficacy, inhibitor, outcome, PD-1 | Leave a comment »
Johnson & Johnson has just acquired the rights to develop and sell a drug called niraparib for the treatment of prostate cancer everywhere in the world except Japan. The developer, Waltham, MA-based Tesaro, has retained the rights to niraparib in Japan. … READ MORE …
Filed under: Drugs in development | Tagged: advanced, inhibitor, niraparib, PARP, trials | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 